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Reversed phase HPLC for strontium ranelate: Method 
development and validation applying experimental design
A reverse-phase HPLC (RP-HPLC) method was develop ed 
for strontium ranelate using a full factorial, screening 
experimental design. The analytical procedure was vali-
dated according to international guidelines for linearity, 
selectivity, sensitivity, accuracy and precision. A separate 
experimental design was used to demonstrate the robust-
ness of the method. Strontium ranelate was eluted at 4.4 
minutes and showed no interference with the excipients 
used in the formulation, at 321 nm. The method is linear 
in the range of 20–320 μg mL–1 (R2 = 0.99998). Recovery, 
tested in the range of 40–120 μg mL–1, was found to be 
96.1–102.1 %. Intra-day and intermediate precision RSDs 
ranged from 1.0–1.4 and 1.2–1.4 %, resp. The limit of detec-
tion and limit of quantitation were 0.06 and 0.20 μg mL–1, 
resp. The proposed technique is fast, cost-effective, reli-
able and reproducible, and is proposed for the routine 
analysis of strontium ranelate.
Keywords: strontium ranelate, HPLC, experimental design, 
full factorial design
Strontium ranelate (SrR, Protelos®, Osseor®) behaves as a dual acting bone agent by 
inhibiting osteoclast activity and at the same time promoting osteoblast differentiation 
and maturation (1). Although several controversies emerged regarding the risk/benefit 
ratio, as a result communicated by the Pharmacovigilance Risk Assessment Committee 
(PRAC) of the European Medicine Agency in April 2014, SrR remained in therapy, with 
further restrictions (2), as a cost-effective alternative for the treatment of osteoporosis in 
both male and female patients.
Structurally, SrR is a di-strontium salt of 2-(2-carboxy-4-cyano-5-[N,N-di(carboxy-
meth yl)amino]thiophene-3-yl) acetic acid (ranelic acid) (Fig. 1).
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Literature data of the active substance revealed that only a few analytical methods 
have been developed for the assay of strontium ranelate, including HPLC (3–5), HPTCL (6), 
UV spectrophotometry (7, 8), capillary electrophoresis (9) and others (10, 11). 
The up-to-date ”quality by design” approach has been successfully used in the phar-
maceutical development and characterisation of tablets, optimization of tablet formula-
tions (12, 13) and also for the analytical method development and validation of HPLC (14, 
15) and other analytical methods (16). Design of experiments (DoE) has many advantages 
in pharmaceutical drug formulations and analytical method development and validation 
in comparison with techniques like changing one factor at a time (COST). While tradi-
tional developmental approaches are mainly empirical and are often conducted using the 
COST method, DoE implies the possibility of performing systematic and multivariate ex-
periments in order to fully understand the process and product characteristics (17–19). The 
reported HPLC methods (3–5) use a multicomponent solvent system and laborious sample 
preparation as well as conventional method development and validation.
The main goal of the present study was to develop a high throughput HPLC method 
for quality control of strontium ranelate, which fulfils method validation requirements 
requested by international guidelines (20). Also, we investigated the effectiveness of a 
computational design approach for method development and validation.
EXPERIMENTAL
Reagents
The active pharmaceutical ingredient SrR octahydrate (22.5 % water determined by 
the Karl-Fischer titrimetric method, γ = 99.2 % by HPLC) was from Dishman Pharmaceu-
ticals and Chemicals, India. Methanol (MeOH) and trifluoroacetic acid (TFA) used were 
from Merck, Germany. Mannitol (Pearlitol 300DC, Ph. Eur., Roquette Pharma, France), 
maltodextrin (Lycatab DSH, Ph. Eur., Roquette Pharma) and aspartame (Ph. Eur., Sigma 
Aldrich, USA) were used for selectivity studies. Osseor® 2g – granules for oral suspension 
(Lés Laboratoires Servier, France) was purchased from a local pharmacy.
Preparation of standard solution
For the stock solution, 8 mg of SrR octahydrate was weighed in a 100-mL volumetric 
flask and made up with TFA 0.1 (0.1 %, V/V) to the mark. The final solution was stirred on 















B. Kovacs et al.: Reversed phase HPLC for strontium ranelate: Method development and validation applying experimental design, 
Acta Pharm. 68 (2018) 171–183.
 
an ultrasound bath for 2 min and filtered through 0.45-μm Whatman® nylon filters (General 
Electric Healthcare, UK) in brown HPLC vials. The first 2 mL of the filtered solution were 
discarded.
Chromatographic conditions and apparatus
HPLC separations were performed with an Agilent 1260 Infinity system with Open-
LAB CDS software (Agilent Technologies, USA), using a RP-HPLC column, Inertsil ODS-3, 
4.6 × 250 mm, 5 μm porosity (GL Sciences, Japan). The optimized isocratic mobile phase 
was composed of MeOH and TFA (0.1 %, V/V) in the proportion 52:48 (V/V). The samples 
(20 μL) were injected using an auto sampler and a quaternary pump with degasser. Signal 
detection was carried out with a diode array detector at 321 nm. All analyses were per-
formed at 34 °C.
Method optimization using design of experiments (DoE)
Experimental design. – In order to optimize the mobile phase composition and ambient 
conditions of the HPLC system, we performed a screening type, full factorial design (op-
timization) with three centre points using MODDE 11.0 software (Umetrics, Sweden). The 
factors defined in the current model are as follows: mobile phase composition, flow rate 
and column temperature. Taking into consideration that the mobile phase composition 
and flow rate were defined at three levels, and column temperature at two levels, the full 
factorial design returned 21 experiments (32 = 9 runs in our case, where 3 represents the 
levels defined, and 2 in the exponent stands for the number of factors. Respective experi-
ments were performed for both lower and higher temperature settings, yielding 18 runs, 
and resulting in a total of 21 runs with centre pointed experiments). Experiments were run 
in replicate samples and peak asymmetry, theoretical plate numbers and retention times 
being noted as responses (Table I).
Table I. Selected factors and responses for full factorial, screening experimental design
Factors used in the experimental design
Level applied –1 0 +1
Mobile phase composition 
(methanol proportion, %) 20 50 90
Flow rate (mL min–1) 0.5 1.0 1.5
Column temperature (°C) 30 40 50
Responses defined for experimental evaluation
Requirement Min Target Max
Peak asymmetry 0.8 1 1.5
Theoretical plate number (N)a 1000 – –
Retention time (min) 3 5 7
a Defined per column length.
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Model fitting. – The model was fitted using the partial least squares (PLS) method. The 
experimental model was characterised based on the significance of the regression model 
using the analysis of variance (ANOVA) and its lack of fit test, and the model performance 
indicators.
Evaluation of experimental design. – The summary of fit plot represents the model per-
formance indicators: the leftmost bar represents the goodness of fit (R2), being an indicator 
of how well the regression model can be made to fit raw data. Taking into account that R2 
alone is not sufficient to evaluate the validity of a model, goodness of predictability – sec-
ond bar – (Q2) is a useful indicator and estimates the predictive power of the model. In 
general, a model is judged as good if the difference between goodness of fit (R2) and good-
ness of predictability (Q2) is lower than 0.2–0.3, otherwise indicating an inappropriate and 
insignificant model, and at the same time it is desirable for Q2 values to be higher than 0.5. 
The third and rightmost bars represent model validity and reproducibility, resp. Model 
validity describes the appropriateness of the selected type of model in general sense and 
is accepted if it returns a reference value greater than 0.25 (17). Taking into consideration 
that when the pure error is very small (replicate results almost identical), model validity 
can be low even though the model is good and complete (18). Finally, model reproducibil-
ity gives information about the control of the experimental procedure; the higher the nu-
merical value (> 0.5), the smaller is the replicate (pure) error. Also, evaluation of raw data 
should be performed on the basis of the coefficient plots of selected responses. Coefficient 
plots represent the dominating factors of the responses and the direction in which the 
influence is powerful. Based on the coefficient plots, model refinement is performed by 
deleting insignificant factors to response interactions (p > 0.05) (17, 19, 21).
Optimization. – After model fitting and refinement, an optimizer run was performed 
and factor settings were defined using the prediction spreadsheet function.
Validation of the optimized analytical method
The developed method based on the DoE optimizer was validated according to inter-
national guidelines (20). 
Linearity. – Linearity was investigated in the range of 20–320 μg mL–1 at 11 points (20, 
40, 60, 70, 80, 90, 100, 120, 160, 240, 320 μg mL–1) repeated five times for each concentration. 
Solutions were prepared from the stock solution of 400 μg mL–1.
Selectivity. – Selectivity studies were performed according to the qualitative and quan-
titative composition of the original product, Osseor® 2 g-granules for oral suspension. The 
pharmaceutical formulation was prepared from mannitol 4.0 g, maltodextrin 0.4 g and 
aspartame 0.02 g per dose. Samples containing individual excipients, a placebo mixture 
and placebo spiked with SrR were prepared and analysed under the same conditions (dis-
solved in TFA 0.1 %, V/V, and using the same mobile phase).
Accuracy (recovery). – Accuracy testing was performed using placebo samples spiked 
with SrR (50, 75, 100, 125 and 150 % of the working concentration, repeated three times for 
each concentration).
Robustness. – Method robustness was tested using a separate experimental design 
(Plackett-Burman model fitted with multiple linear regression, MLR) with three centre points. 
The Plackett-Burman (PB) design is an orthogonal two-level experimental design, which 
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allows to test a large number of factors, but no factor interactions can be evaluated. Taking 
into consideration that robustness testing implies linear analysis of the factors and responses, 
the PB model represents one of the commonly used designs for method robustness testing. 
After model fitting and raw data evaluation, various outcomes of robustness testing are to be 
considered on the basis of the R2 and Q2 values: i) inside specification and significant model, 
ii) inside specification and insignificant model, iii) outside specification and significant model, 
iv) outside specification and insignificant model. The second limiting case (results inside 
specification and insignificant model) represents the optimal outcome of robustness testing, 
since all results are situated in-between the specification limits and no significant relationship 
is observed between the factors and responses (17). The factors defined for the experimental 
design were the same as described in DoE optimization, with the following intervals: metha-
nol proportion 50–54 % (V/V), flow rate 0.65–0.75 mL min–1, column temperature 32–36 °C. 
The investigated factors were defined at two levels, resulting in 11 experiments. The experi-
ments were run in two replicates, and the responses were the same as defined in optimization 
DoE, respecting the corresponding intervals in all three cases.
Furthermore, method robustness was tested for individual changes of the detection 
wavelength (319 and 323 nm) and filter type (regenerated cellulose 0.22-μm filter vs. routine 
analysis filter).
Limit of detection (LOD) and limit of quantitation (LOQ). – Limit of detection (LOD) and 
limit of quantitation (LOQ) were defined as concentrations at a signal-to-noise ratio of 3:1, 
for six replicate determinations, and at a signal-to-noise ratio of 10:1, for three replicate 
determinations.
Precision. – Samples containing Osseor® granules, corresponding to 6.24 g SrR anhy-
drous, were prepared and analysed six times on a single day and on different days by two 
analysts. 
Statistical analysis
Statistical analyses were performed using Minitab 17 software (Minitab Inc., State 
College, PA, USA) and Statistica 8.0 software (StatSoft, Tulsa, OK, USA).
Outlier values from the experimental designs were detected using Grubb’s test for 
outliers at a significance level of α = 0.05 (p < 0.05).
Normal distribution of the residuals for linearity testing was demonstrated by the 
Shapiro-Wilk test (confidence interval of 95 %), and the normality test for residuals was 
also assessed by a Q-Q plot. The test was considered significant if the W value calculated 
for the analyte was higher than the critical tabulated value and p < 0.05, simultaneously. 
Linearity acceptance was also assessed, based on the relative standard deviation of subse-
quent injections for each concentration (requirement: < 2 %), and the plot of response versus 
the corresponding concentration values was calculated with an acceptance limit of 2.5 % 
of the target level response factor. Calibration curve significance was tested with ANOVA 
F-test and its test for lack of fit (confidence limit of 95 %). Process capability was calculated 
for the plot of response vs. concentration values in order to assess the ability of the process 
to perform within the specification limits (acceptance value Cpk > 1.33).
Student’s t-test was used in order to statistically compare the result sets of intra-day and 
intermediate precision, statistical significance being set at a confidence level of 95 % (22).
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RESULTS AND DISCUSSION
Screening experimental design (optimization)
Two experiments were excluded from this procedure due to inappropriate retention 
times; outlier values were excluded from the design as well. The results are presented in 
Table II.







































































1a 21 20 0.5 30 – 27.350b –
2 14 50 0.5 30 1.450 6.550 6 747.0
3 1 90 0.5 30 0.845 5.865 319.5
4 6 20 1 30 1.150 15.730b 966.0
5 11 50 1 30 1.260 3.285 4 790.5
6 18 90 1 30 0.655 3.085 836.0
7a 13 20 1.5 30 – – –
8 4 50 1.5 30 1.210 2.190 3 613.5
9 17 90 1.5 30 1.215 1.885 532.5
10 16 20 0.5 50 1.230 18.35b 2 259.0
11 15 50 0.5 50 1.340 6.030 6 135.5
12 2 90 0.5 50 0.985 5.585 314.5
13 19 20 1 50 1.160 9.440 7 357.5
14 5 50 1 50 1.210 2.995 4 318.5
15 10 90 1 50 2.615b 2.710 340.0
16 12 20 1.5 50 1.160 6.060 5 545.0
17 3 50 1.5 50 1.155 1.990 3 388.0
18 7 90 1.5 50 0.925 1.880 578.5
19 8 50 1.0 40 1.305 3.120 4 948.0
20 20 50 1.0 40 1.255 3.125 5 073.5
21 9 50 1.0 40 1.295 3.120 4 815.5
N – number of theoretical plates per column length.
a Excluded experiments: experiments No. 1 and No. 7 were excluded, because the active substance under the set of 
chromatographic conditions showed inappropriate retention time.
b Outlier values.
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For all three responses (peak asymmetry, retention time, theoretical plate number), 
significant regression models were obtained (p < 0.05) and lack of fit was observed (p < 0.05) 
in some cases. This phenomenon is also sustained by low model validity for all responses 
(< 0.25). In contrast to low model validity, model reproducibility showed high values (≈0.99) 
for all responses, since the replicate runs (Table II, exp. nos. 19–21) returned almost identi-
cal results, meaning that pure error inside the model was very low, as desirable for repli-
cate HPLC injections. As the pure error inside the model tends to zero, low model validity 
is explained by the high reproducibility of experimental runs. Moreover, extremely good 
reproducibility (> 0.9) is advantageous in HPLC screening designs, in comparison with 
model validity, as lower reproducibility results (usually < 0.5) indicate a large pure error 
inside the model and poor control of the experimental procedure.
The other model performance indicators represent a good model, R2 values ranging 
from 0.63 to 0.99 and Q2 values greater than 0.5 (0.54–0.87) (Fig. 2a).
Peak asymmetry is strongly influenced by methanol proportion in the mobile phase, 
this being inversely proportional to the value of peak asymmetry. Similarly, the theoretical 
plate number shows a negative correlation with the quantity of methanol in the mobile 
phase. Methanol proportion and flow rate had a powerful impact on retention time; in-
verse proportionality was found (Fig. 2b). Also, quadratic terms of the methanol propor-
tion (%MeOH × %MeOH) had a significant impact on all responses, flow rate (flow × flow) 
influencing only retention time in a significant manner. As a consequence, these qua-
dratic terms were retained during model fitting, since their deletion would result in model 
performance indicator (R2, Q2) deterioration. Furthermore, the presence of these quadratic 
Fig. 2. a) Summary of the fit of screening DoE (optimization), b) correlation plot of responses of 
screening DoE (optimization), c) summary of the fit of Plackett-Burman model (robustness testing), 
d) correlation plot of responses of Plackett-Burman model (robustness testing).
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terms indicates a non-linear blending of the effects, and the presence of a curved surface 
inside the model.
After model fitting, the samples were injected five times using the parameters found 
as the optimal set provided by the software. The conditions set, using the prediction 
spreadsheet function are displayed in Table III.
The results obtained after five successive injections for the optimal set of chromato-
graphic conditions showed a good correlation with the predicted values, the theoretical 
plate number being the farthest from the predicted values, but still lying inside the fore-
seen interval. Under optimized conditions, the analyte eluted at the retention time around 
4.4 min (mean 4.42 min, RSD = 0.4 %) as predicted by the software (Fig. 3b). Peak asym-
metry resulted in the mean value of 1.32 (RSD = 1.4 %), being marginally higher than the 
predicted value. The theoretical plate number resulted in 5755 (RSD = 2.4 %), a value high-
er by 1167 compared to the value predicted by the software.
Validation of optimized chromatographic method
Stability of the stock solution. – Stability of the active pharmaceutical ingredient in the 
solution (TFA 0.1 %, V/V) was followed for 168 hours. Degradation of the active substance 
was ≤ 2 % after 8 hours, reaching approx. 30 % decomposition after the target test period.
Selectivity. – The performed selectivity studies show that SrR could be identified as a 
sharp, well distinct peak at 321 nm, with no interference from the excipients (Fig. 3c). In the 
case of mannitol and aspartame, no peak was observed at the proposed detection wave-
length, while maltodextrin showed a small peak at 3.71 min (Fig. 3a), with resolution of 
2.71 to SrR.
Linearity. – The method was found to be linear in the range of 20–320 μg mL–1, with 
the coefficient of determination R2 > 0.99998. Relative standard deviation for each concen-
tration was < 1.5 % for replicate injections, and the plot of response values referring to the 
target concentration was < 1.0 %. Statistical analysis revealed that the residuals followed 
Table III. Optimized chromatographic conditions based on the experimental design, and predicted results for 
the proposed settings
Optimized chromatographic conditions according to DoE
Methanol (%) Flow rate (mL min–1) Column temperature (°C)
52 0.7 34
Predicted results







Values in brackets indicate the 95 % confidence intervals around the predicted response values.
a N defined per column length.
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normal distribution, since the obtained W-value for strontium ranelate was superior to the 
critical tabulated value for the Shapiro-Wilks test (WSrR > Wa, p > 0.05). Moreover, a strong 
linear relationship between the responses and predictors (FSrR > Fc, p < 0.05) and no lack-of-
fit was observed inside the regression model (FSrR < Fc, p > 0.05), since the F-values for 
strontium ranelate have greater values for relationship testing and smaller values for lack-
of-fit testing in comparison with the critical tabulated values for the ANOVA F-test and its 
lack-of-fit test, resp. The process capability assessed for the calculated plot of response 
values vs. concentration is greater than the acceptance limit of 1.33, indicating that the 
output of the model (responses vs. predictors) is well controlled and within limits. Statisti-
cal results are given in Table IV.
Fig. 3. Typical chromatograms of: a) placebo formulation, b) strontium ranelate from bulk, c) strontium 
ranelate spiked sample. Key for the peaks: 1 – maltodextrin (tR = 3.71 min), 2 – Sr-ranelate (tR = 4.41 min).
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Accuracy (recovery). – Recovery varied from 96.1 to 102.1 % in the tested range. Linearity 
of the spiked samples was also verified, showing a good linear correlation with R2 = 0.998. 
Recovery was found to be in the range of 98.2–101.3 % for concentration levels from 80–120 % 
of the working concentration.
Robustness. – The method proved to be robust in the tested range, with low goodness 
of fit (R2 = 0.02–0.24) and negative goodness of predictability (Q2 = –0.49 to –0.22) values, 
indicating that minor changes in factor settings did not influence the responses (peak 
asymmetry and theoretical plate numbers) in a significant manner, the results being within 
the specification limits under the tested factor settings.
 Furthermore, the negative goodness of predictability indicated that the software 
could not foresee conspicuous variations in results for minor changes in factor settings. 
This was due to homogenous results of the responses under the tested factor intervals.
In contrast to the DoE performed for factor screening, model validity bars were > 0.5 
for all three responses (peak asymmetry, theoretical plate number, retention time), indicat-
ing that the method had a good validity in the proposed setting range (Fig. 2c).
Peak asymmetry and theoretical plate number were not influenced by minor changes 
in mobile phase composition, column temperature and flow rate. However, retention time 
was sensitive to minor factor setting modifications, showing a strong negative correlation 
Table IV. Validation parameters for HPLC determination of strontium ranelate
Parameter Result Statistical results
Linearity (μg mL–1) 20–320 
R2 = 0.99998 
WSrR = 0.949 (p = 0.63)a 
FSrR = 277,769.94 (p < 0.05)b 
F = 0.29 (p = 0.975)c 
Cpk = 2.47d
Accuracy (%)e 99.1 ± 1.7 R2 = 0.998
Intra-day precision (RSD, %)f,g 1.0–1.4
t<analyst 1 day 1> = 0.225 (p = 0.826) 
t<analyst 1 day 2> = 0.04 (p = 0.969) 
t<analyst 2 day 2> = 0.02 (p = 0.986)
Inter-day precision (RSD, %)f,h 1.2–1.44 t<analyst 1 day 1 vs. day 2> = 0.770 (p = 0.452) t<analyst 1 vs. analyst 2> = 1.250 (p = 0.226)
Instrument precision (RSD, %)e 0.1
LOD (μg mL–1) 0.06
LOQ (μg mL–1) 0.20
a Critical tabulated value of Shapiro-Wilk’s test: Wa = 0.850 (WSrR – Shapiro-Wilk’s test results for strontium ranelate).
b Critical tabulated value of ANOVA F-test: Fc = 2.649 (FSrR – ANOVA F-test results for strontium ranelate).
c Critical tabulated value of ANOVA F-test for lack-of-fit: Fc = 2.14.
d Cpk > 1.33 (Cpk – process capability index).
e n = 5.
f n = 6.
g Critical value of t = 2.228, df = 10.
h Critical value of t = 2.074, df = 22.
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with the proportion of methanol in the mobile phase and the applied flow rate (Fig. 2d). 
These observations are in accord with the results of DoE screening used for optimization 
of the method.
The tested changes in sample preparation (use of regenerated cellulose filter) and 
signal detection had no significant impact on the chromatographic results; peak asymme-
try, retention time, and theoretical plate numbers were not influenced by the investigated 
factors.
Precision. – Method precision was assessed using Osseor® granules for oral suspen-
sion. The intra-day and intermediate precision showed low variability between samples, 
RSD values being less than 2 % for all samples. The performed Student’s t-test revealed 
that there was no statistically significant difference between the result sets obtained by the 
same analyst on the same day and inter-day, nor between two analysts on the same day, 
indicating that the method provided good intra-day and intermediate precision (Table IV).
Limit of detection and limit of quantitation. – LOD and LOQ for strontium ranelate, ex-
pressed for the anhydrous form, were 0.06 and 0.20 μg mL–1, resp.
Preliminary method applicability
The assay of strontium ranelate in Osseor® granules resulted in 99.18 % of active sub-
stance according to the label claim, with good precision (RSD < 2 %).
Method benefits
Unlike the disclosed methods already available for the assay of strontium ranelate, the 
proposed novel method has shorter sample preparation time, thus offering a high through-
put of sample analysis.
This assay works within a wider linearity range and shows superior LOD and LOQ 
values. Furthermore, signal detection is carried out at 321 nm, where no interference was 
observed with the excipients present in the original product composition.
CONCLUSIONS
The suggested method turned out to be an easy, rapid and cost-effective analytical 
tool for assaying strontium ranelate in bulk samples and, as expected, in pharmaceutical 
dosage forms. A computational approach to the design of experiments was used to gain as 
much knowledge about the chromatographic system as possible. The applied experimental 
designs for method optimization and robustness testing proved to be adequate and can be 
used for analytical method development. Furthermore, the method proved to meet all 
validation requirements (linearity, accuracy, sensitivity, robustness, precision) requested 
by most international guidelines. In addition, the computational method development of-
fered extensive knowledge about the HPLC system, including the possibility to gather in 
silico information about the responses that characterise the developed analytical method 
by modifying factor settings.
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